PubMed Health⌕ Search

PubMed · 11746328

Correcting for measurement error in binary and continuous variables using replicates.

Abstract

Measurement error in exposures and confounders leads to bias in regression coefficients. It is possible to adjust for this bias if true values or independent replicates are observed on a subsample. We extend a method suitable for quantitative variables to the situation where both binary and quantitative variables are present. Binary variables with independent replicates introduce two extra problems: (i) the error is correlated with the true value, and (ii) the measurement error probabilities are unidentified if only two replicates are available. We show that - under plausible assumptions - adjustment for error in binary confounders does not need to address these problems. The regression coefficient for a binary exposure is overadjusted if methods for continuous variables are used. Correct adjustment is possible either if three replicates are available, or if further assumptions can be made; otherwise, bounds can be put on the correctly adjusted value, and these bounds are reasonably close together if the exposure has prevalence near 0.5.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

I White, C Frost, S Tokunaga. 2001-11-30. Correcting for measurement error in binary and continuous variables using replicates.. https://doi.org/10.1002/sim.908

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Assessment of blinding in pharmacotherapy and noninvasive neuromodulation randomized controlled trials for neuropathic pain in adults.

In randomized controlled trials (RCTs), study participants and research personnel are often blinded to minimize biases related to knowing treatment allocation. To determine if blinding was effective, participants may be asked which treatment they believe they received ("treatment guess"). This descriptive review characterized blinding assessment (BA) reporting in pharmacotherapy and neuromodulation neuropathic pain RCTs. Of 288 papers, 36 (12.5%) reported a BA. One paper reported the results of 2 studies, so in total 37 studies with a BA were assessed. Of these, 19 were crossover, 17 parallel, and 1 partial crossover in design. All 37 studies assessed participant blinding, and 10 also assessed investigator blinding. Approximately 27% included an "unsure" answer option for treatment guess, and 38% asked the reason for the guess. There were no clear patterns in BA reporting across time nor based on treatment type. Seventeen trials provided sufficient data to calculate Bang Blinding Index (BI) to determine blinding success. Participants remained blinded (BI = 0 &#xb1; 0.2) in 10/17 placebo and 10/17 treatment arms, 6 placebo and 5 treatment arms had a BI > 0.2 suggesting possible unblinding, whereas 1 placebo and 2 treatment arms had a BI < -0.2 suggesting misinformed guessing. Overall, we found that BAs are done in a minority of published neuropathic pain trials and with variable methodology. Given the importance of minimizing risk of bias because of treatment unblinding, future studies should consider including BAs, and further consensus building is necessary to determine if and how BAs should be conducted and interpreted in analgesic clinical trials.

Bias↗